Interestingly, SSc patients with a lower variation of IGFBP-2 (less than 22%) presented significant deterioration of pulmonary function at 2-year follow-up (KCO %pred at baseline: 77 (± 12) % and 2-year follow-up: 66 (± 9) %, p < 0.01), whereas the ones with higher variation of IGFBP-2 (more than 22%) conserved their pulmonary function (Fig. 4c). Here, IGFBP2 is linked to systemic sclerosis.